VCM
COGT icon

Versant Capital Management’s Cogent Biosciences COGT Stock Holding History

Versant Capital Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.58K Sell
170
-11
-6% -$385 ﹤0.01% 2365
2026
Q1 		$6.97K Buy
181
+11
+6% +$406 ﹤0.01% 2282
2025
Q4 		$6.04K Hold
170
– – ﹤0.01% 2178
2025
Q3 		$2.44K Hold
170
– – ﹤0.01% 2378
2025
Q2 		$1.22K Buy
+170
New +$942 ﹤0.01% 2461

Other funds holding COGT

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
HIA
Harbor Investment Advisory Lutherville, Maryland $1.43B AUM 30.71% 1-Year Est. Return

Versant Capital Management's COGT Position: Q2 2026 in Review

Versant Capital Management reduced its Cogent Biosciences (COGT) stake by 6.1% in Q2 2026, selling an estimated $385 and leaving 170 shares worth $6.58K. The position accounts for ﹤0.01% of the portfolio, ranked #2365.

Versant Capital Management first reported a position in COGT in Q2 2025 and has held it in 5 quarters since. The position peaked at $6.97K in Q1 2026. 18 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Versant Capital Management held 170 shares of Cogent Biosciences worth $6.58K as of Q2 2026.
  • Versant Capital Management sold 11 Cogent Biosciences shares in Q2 2026, an estimated $385.
  • Cogent Biosciences made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2365 holding.
  • Versant Capital Management first reported a position in Cogent Biosciences in Q2 2025 and has held it in 5 quarters since.
  • Versant Capital Management's Cogent Biosciences position peaked at $6.97K in Q1 2026.
  • 18 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.